TranScrip Partners LLP announced the appointment of two new senior partners, Julia Lloyd-Parks and Mark Watling. The move is set to further enhance the organisation’s high level expertise in clinical research, clinical development and medical affairs across multiple therapeutic areas. This latest recruitment initiative sees TranScrip expecting to exceed 30 partners, as two more hires are expected this year, with plans afoot for further expansion in 2011.
Julia Lloyd-Parks brings 30 years worth of clinical and drug development expertise to the partnership and is a seasoned expert in anti-infectives, cardiovascular, immunology and transplant therapeutics. She has held clinical research posts in Novartis, Syntex and Innovex. Her responsibilities in these companies covered Phase I to Phase III development programmes, medical information and coordinating international clinical research operations. Julia also worked for Technomark, the industry consulting group, prior to heading up the ant-infectives and immunology project management group at Daiichi Sankyo.
Julia, who gained an M.Sc. in Information Science from City University, London, is an Honorary Fellow of the Institute of Clinical Research.
Mark Watling is a senior pharmaceutical physician with more than 18 years experience in clinical development. Mark served as Medical Director at Cephalon, Head of Medical Partnership at Novo Nordisk and Group Medical Director at Archimedes Pharma, leading teams engaged in the development and approval of CNS, neurology, pain and critical care products. Specific responsibilities included medical support to product commercialisation, through the development of in-house and contracted services that encompassed medical liaison, medical information and pharmacovigilance. He also has CRO experience and was responsible for designing and implementing programmes at both Til Occam and Quintiles.